Evidence map›Paper›PMID 32086768›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2020

Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22).

Xue-Lian Zhang, Gang Wan, Ming-Xia Yuan, Guang-Ran Yang, Han-Jing Fu, Liang-Xiang Zhu, Rong-Rong Xie, Yu-Jie Lv, Jian-Dong Zhang, Yu-Ling Li and 5 more

Abstract read
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xue-Lian Zhang *Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Gang Wan *Medical records and Statistics Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Ming-Xia YuanDepartment of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Guang-Ran YangDepartment of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Han-Jing FuDepartment of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Liang-Xiang ZhuDepartment of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Rong-Rong XieDepartment of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Yu-Jie LvCuigezhuang Community Health Service Center, Beijing, China.
Jian-Dong ZhangJinsong Community Health Service Center, Beijing, China.
Yu-Ling LiXinjiekou Community Health Service Center, Beijing, China.
Qin-Fang DaiYuetan Community Health Service Center of Fuxing Hospital, Capital Medical University, Beijing, China.
Yu JiDepartment of Endocrinology, Beijing Aerospace General Hospital, Beijing, China.
Rury R HolmanDiabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. rury.holman@dtu.ox.ac.uk.
Shen-Yuan YuanDepartment of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. fulvic@126.com.
Beijing Communities Diabetes Study Group

Funding

Beijing Municipal Science &Technology Commission Z151100004015021Grant of Special Scientific Research on Capital Health Development 2016-1-2054Grant of Special Scientific Research on Capital Health Development 2016-1-2057
6 · The paper itself

Abstract

introductionTo date, research is lacking on the development of a cardiovascular disease (CVD) risk assessment tool for people with diabetes mellitus, in general, and for Chinese patients with diabetes in particular. We have explored CVD risk assessment tools for Chinese patients with diabetes. Here, we report our investigation of cardiovascular risk assessment using the improved Framingham Risk Score (I-FRS) in patients with type 2 diabetes mellitus (T2DM) in Beijing communities.

methodsA total of 3232 patients with T2DM attending Beijing community health centers were enrolled in this study. FRS were used to predict CVD risk in all patients at baseline using the following risk scores for glycated hemoglobin (HbA1c) categories: 0 = HbA1c ≤ 7.0%; 1 = 7.0% < HbA1c  ≤ 7.9%;      2 = 8.0% < HbA1c ≤ 8.9%; and 3 = HbA1c > 9.0%. The I-FRS was use to stratify all patients into low (I-FRS < 10%), medium (I-FRS 10-20%), and high (I-FRS > 20%) FRS strata. All treatments administered in the Beijing Communities Diabetes Study were in accordance with national guidelines for T2DM in China, and patients regularly attended clinical consultations with professors in endocrinology, who were experts in their respective speciality, from top tier hospitals. After 10 years, patients were followed-up to assess the long-term effects of the multifactorial interventions. Statistical analysis was performed using SAS® software (SAS Institute, Inc., Cary, NC, USA).

resultsThe receiver operating characteristic curve of the I-FRS showed significant prediction accuracy for the actual incidence of CVD events. At baseline, subjects in the high FRS stratum for diabetes were more prone to be elderly and to have a longer duration of T2DM, higher systolic blood pressure, and higher lipid profiles. Subjects in the medium and high FRS strata had a higher incidence of CVD events than those in the no-complications group (DM group with no blood pressure issues) (P < 0.001). The 10-year hazard ratios for CVD events in diabetic patients with I-FRS score > 20% was 12.5-fold higher than that of patients with I-FRS score < 10%. Multifactorial intervention significantly reduced the I-FRS of the three FRS strata in patients with T2DM. The post-intervention I-FRS for the hypertension and CVD groups of patients were significantly lower than the respective baseline I-FRS. Cox multivariate analyses revealed that patients in the medium and high FRS strata had higher incidences of endpoint events than those in the low FRS stratum.

conclusionsThe I-FRS plays an important role in predicting CVD in patients with T2DM. Multifactorial interventions for CVD risk factors over 10-year follow-up lowered the estimated 10-year risk for CVD events in persons with diabetes. We suggest the use of the I-FRS score to stratify a patient's risk of CVD when analyzing the efficacy of diabetes management. Aggressive risk reduction should be focused on those individuals with a high I-FRS score.

trial registrationChiCTR-TRC-13003978 and ChiCTR-OOC-15006090.

Indexed as

Cardiovascular diseaseFramingham Risk ScoreHypertensionThe Beijing Communities Diabetes StudyType 2 diabetes mellitus (T2DM)UKPDS score

Identifiers

PMID32086768
PMCPMC7136369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.